Galecto is focused on developing novel drugs for the treatment of fibrosis, inflammation, and cancer based on targeting galectins, a group of proteins shown to be involved in many disease processes. Galecto’s team of scientists and experts has shown in preclinical and clinical studies that the company’s high potency galectin modulators may open new treatment possibilities for many patients. The company’s lead product, TD139, is an inhaled galectin-3 inhibitor about to enter phase 2/3 studies for the treatment of idiopathic pulmonary fibrosis (IPF). Galecto is located in Copenhagen, Denmark.
Details Galecto Biotech Cobis Ole Maaloes Vej 3 DK-2200 Copenhagen N Denmark www.galecto.com